Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

Incyte INCY announced that the FDA has approved its humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, ...

Creative Biolabs recently rolled out a three-dimensional upgrade designed to make antibodies safer, more potent, and easier to develop. SHIRLEY, NY, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- ...

Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and remission in systemic lupus erythematosus, according to data presented at the EULAR 2025 ...

The partnership will use Debiopharm's AbYlink conjugation tech in combination with Alkyon’s modular antibody platform.

Treated recipients received either 3 mg/kg rapamycin intraperitoneally for the first 14 d after transplantation (days 0-13) and/or 0.25 mg/dose CD40L-specific antibody (days 0, 2, 4, 7 and 10 ...

Analysis of Antibody Drug Conjugates Contract Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan ROCKVILLE, MD, UNITED STATES, June 18, ...

在肿瘤治疗中，相比于化疗药物，近年来生物制药日新月异，尤其是以单克隆抗体为代表的创新药已广泛应用于临床，比如大家耳熟能详的贝伐珠单抗，曲妥珠单抗，帕博利珠单抗等。由于大部分临床医生，不熟悉免疫基础知识，在学术交流中，单克隆抗体抗癌机制部分，令人费解的 ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

The FDA has granted Fast Track designation to nadunolimab to treat patients with previously untreated metastatic pancreatic ductal adenocarcinoma.